Meet the Diagnostics & Personalised Medicine team
Navigating patentability restrictions in Europe – Guardant Health, Inc.
Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through ‘liquid biopsies’. Its tests are centred on the high-sensitivity detection of tumour-derived DNA in blood using comprehensive nucleic acid sequencing-based approaches. This enables early detection, monitoring and personalised treatment for cancer. Guardant’s patent applications span a wide range of technologies, from the initial wet lab techniques used to prepare sequencing libraries, to the bioinformatic analysis of sequencing data. Carpmaels & Ransford has helped Guardant navigate the restrictions surrounding the patentability of computer-implemented and information-based inventions at the EPO, which are increasingly common obstacles in the biotechnology sector.